文档介绍：Ezetimibe Add-on to Statin Therapy for Effectiveness Trial
Presented at
American College of Cardiology
Scientific Sessidl in the coronary heart disease (CHD) or CHD risk equivalent group, 147 mg/dl in the multiple risk factors group, and 167 mg/dl in the <2 risk factors group.
The ezetimibe arm had a larger reduction in triglycerides and a larger increase in high-density lipoprotein (HDL) levels.
Ezetimibe
Placebo
mg/dl
Increase in
High-Density Lipoprotein (HDL)
p<
Ezetimibe
Placebo
Reduction in LDL
p<
Presented at ACC Scientific Sessions 2004
EASE Trial
In the overall study population, a larger percent change from baseline in LDL levels occurred in the ezetimibe arm versus placebo.
The follow-up LDL level in the ezetimibe arm was 95 mg/dl.
A larger percentage of patients in the ezetimibe arm reached target LDL goals.
Results were similar across the different statin brands and by the prespecified subgroups of age group, gender, and diabetes status.
Ezetimibe
Placebo
Reached Target
LDL Goals
p<
mg/dl
Ezetimibe
Placebo
Reduction in LDL
p<
Presented at ACC Scientific Sessions 2004
EASE Trial
Reached Target LDL Goals
p<
mg/dl
Similar results were observed in the CHD/CHD risk equivalent subgroup, the multiple risk factor subgroup, and the <2 CHD risk factor subgroup.
There were no increases in the frequency of alanine aminotransfe